Thrixen
Thrixen is a biotechnology company founded in 2021 by international scientists from Singapore and the USA, originating from SMART (Singapore MIT Alliance for Research and Technology). The company specializes in proprietary technologies that revolutionize biomarker detection and rapid assay generation, enabling diagnostics to be more accessible, affordable, and scalable. Thrixen develops a diagnostic technology platform that makes diagnostics available when and where they matter most, utilizing engineered protein binders and a unique assay format to bring essential diagnostics closer to patients.
Industries
Nr. of Employees
small (1-50)
Thrixen
21 Biopolis Rd, #02-03 Nucleos North Tower, Singapore, 138576
Products
Multiplex point-of-care diagnostic platform
A platform designed to perform rapid, multiplex diagnostic tests on whole blood at the point of care using engineered protein binders and compatible assay formats.
Rapid neutralizing-antibody serology test (research/preprint)
A rapid finger-stick blood test format developed to assess post-vaccination neutralizing antibody response against SARS-CoV-2 variants (reported in preprint and peer-reviewed outlets).
Multiplex point-of-care diagnostic platform
A platform designed to perform rapid, multiplex diagnostic tests on whole blood at the point of care using engineered protein binders and compatible assay formats.
Rapid neutralizing-antibody serology test (research/preprint)
A rapid finger-stick blood test format developed to assess post-vaccination neutralizing antibody response against SARS-CoV-2 variants (reported in preprint and peer-reviewed outlets).
Services
R&D collaborations to design and develop rapid, multiplex point-of-care assays for infectious-disease targets, including whole-blood formats.
Design and screening of engineered protein binders to replace conventional antibodies as affinity reagents in diagnostic assays.
Integration of assays with reader hardware and development of image-analysis software for automated result interpretation.
Verification and validation activities to establish assay performance prior to clinical evaluation or regulatory submission.
R&D collaborations to design and develop rapid, multiplex point-of-care assays for infectious-disease targets, including whole-blood formats.
Design and screening of engineered protein binders to replace conventional antibodies as affinity reagents in diagnostic assays.
Integration of assays with reader hardware and development of image-analysis software for automated result interpretation.
Verification and validation activities to establish assay performance prior to clinical evaluation or regulatory submission.
Expertise Areas
- Point-of-care diagnostics
- Protein engineering and binder selection
- Multiplex assay development
- Biosensor design
Key Technologies
- Engineered protein binders (non-antibody affinity reagents)
- Multiplex point-of-care assay formats
- Paper-based diagnostic devices
- Microfluidics
News & Updates
BARDA is partnering with Thrixen for early product development of a multiplex, rapid, point-of-care (PoC) diagnostic that distinguishes between orthoebolaviruses (Zaire and Sudan) and malaria.
Singapore-based medical technology startup Thrixen is accelerating development of its diagnostic technology platform that has the potential to perform multiplex diagnostic tests at the point of care, following a $7 million seed round.
Thrixen has raised US$7 million in a round co-led by 22Health Ventures and John Ballantyne, to accelerate its development of multiplex diagnostic tests.
Thrixen was selected as one of 24 companies to participate in the 2023 cohort of the MedTech Innovator Asia Pacific Accelerator program.
A finger stick blood test to assess post vaccination SARS-CoV-2 neutralizing antibody response against variants.
A profile highlighting Thrixen’s development of COVID-19 tests that are simple, easy to use, and offer quick, reliable results.
BARDA is partnering with Thrixen for early product development of a multiplex, rapid, point-of-care (PoC) diagnostic that distinguishes between orthoebolaviruses (Zaire and Sudan) and malaria.
Singapore-based medical technology startup Thrixen is accelerating development of its diagnostic technology platform that has the potential to perform multiplex diagnostic tests at the point of care, following a $7 million seed round.
Thrixen has raised US$7 million in a round co-led by 22Health Ventures and John Ballantyne, to accelerate its development of multiplex diagnostic tests.
Thrixen was selected as one of 24 companies to participate in the 2023 cohort of the MedTech Innovator Asia Pacific Accelerator program.
A finger stick blood test to assess post vaccination SARS-CoV-2 neutralizing antibody response against variants.
A profile highlighting Thrixen’s development of COVID-19 tests that are simple, easy to use, and offer quick, reliable results.